SOX7 inhibits the malignant progression of bladder cancer via the DNMT3B/CYGB axis.

IF 6.3 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Molecular biomedicine Pub Date : 2024-09-04 DOI:10.1186/s43556-024-00198-8

Jingcheng Zhang, Wentao Zhang, Ji Liu, Yuchao Liu, Yufeng Jiang, Ailiyaer Ainiwaer, Hanyang Chen, Zhuoran Gu, Haotian Chen, Shiyu Mao, Yadong Guo, Tianyuan Xu, Yunfei Xu, Yuan Wu, Xudong Yao, Yang Yan

{"title":"SOX7 inhibits the malignant progression of bladder cancer via the DNMT3B/CYGB axis.","authors":"Jingcheng Zhang, Wentao Zhang, Ji Liu, Yuchao Liu, Yufeng Jiang, Ailiyaer Ainiwaer, Hanyang Chen, Zhuoran Gu, Haotian Chen, Shiyu Mao, Yadong Guo, Tianyuan Xu, Yunfei Xu, Yuan Wu, Xudong Yao, Yang Yan","doi":"10.1186/s43556-024-00198-8","DOIUrl":null,"url":null,"abstract":"<p><p>Bladder cancer (BCa) stands out as a highly prevalent malignant tumor affecting the urinary system. The Sex determining region Y-box protein family is recognized for its crucial role in BCa progression. However, the effect of Sex determining region Y-box 7 (SOX7) on BCa progression has not been fully elucidated. Herein, RNA-sequencing, western blot (WB), immunohistochemistry (IHC), immunofluorescence (IF) and tissue microarray were utilized to assess SOX7 expression in vitro and in vivo. Additionally, SOX7 expression, prognosis, and SOX7 + cytoglobin (CYGB) score were analyzed using R software. In vitro and vivo experiments were performed with BCa cell lines to validate the effect of SOX7 knockdown and overexpression on the malignant progression of BCa. The results showed that SOX7 exhibits low expression in BCa. It functions in diverse capacities, inhibiting the proliferative, migratory, and invasive capabilities of BCa. In addition, the experimental database demonstrated that SOX7 binds to the promoter of DNA methyltransferase 3 beta (DNMT3B), leading to the transcriptional inhibition of DNMT3B. This subsequently results in a reduced methylation of CYGB promoter, ultimately inhibiting the tumor progression of BCa. SOX7 + CYGB scores were significantly linked to patient prognosis. In conclusion, SOX7 inhibits the malignant progression of BCa via the DNMT3B/CYGB axis. Additionally, the SOX7 + CYGB score is capable of predicting the prognostic outcomes of BCa patients. Therefore, SOX7 and CYGB may play an important role in the progression of bladder cancer, and they can be used as prognostic markers of bladder cancer patients.</p>","PeriodicalId":74218,"journal":{"name":"Molecular biomedicine","volume":null,"pages":null},"PeriodicalIF":6.3000,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11371982/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular biomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s43556-024-00198-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Bladder cancer (BCa) stands out as a highly prevalent malignant tumor affecting the urinary system. The Sex determining region Y-box protein family is recognized for its crucial role in BCa progression. However, the effect of Sex determining region Y-box 7 (SOX7) on BCa progression has not been fully elucidated. Herein, RNA-sequencing, western blot (WB), immunohistochemistry (IHC), immunofluorescence (IF) and tissue microarray were utilized to assess SOX7 expression in vitro and in vivo. Additionally, SOX7 expression, prognosis, and SOX7 + cytoglobin (CYGB) score were analyzed using R software. In vitro and vivo experiments were performed with BCa cell lines to validate the effect of SOX7 knockdown and overexpression on the malignant progression of BCa. The results showed that SOX7 exhibits low expression in BCa. It functions in diverse capacities, inhibiting the proliferative, migratory, and invasive capabilities of BCa. In addition, the experimental database demonstrated that SOX7 binds to the promoter of DNA methyltransferase 3 beta (DNMT3B), leading to the transcriptional inhibition of DNMT3B. This subsequently results in a reduced methylation of CYGB promoter, ultimately inhibiting the tumor progression of BCa. SOX7 + CYGB scores were significantly linked to patient prognosis. In conclusion, SOX7 inhibits the malignant progression of BCa via the DNMT3B/CYGB axis. Additionally, the SOX7 + CYGB score is capable of predicting the prognostic outcomes of BCa patients. Therefore, SOX7 and CYGB may play an important role in the progression of bladder cancer, and they can be used as prognostic markers of bladder cancer patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

SOX7 通过 DNMT3B/CYGB 轴抑制膀胱癌的恶性进展。

膀胱癌（BCa）是一种影响泌尿系统的高发恶性肿瘤。性别决定区 Y-box 蛋白家族被认为在 BCa 进展过程中起着关键作用。然而，性别决定区 Y-box 7（SOX7）对 BCa 进展的影响尚未完全阐明。本文利用RNA测序、Western印迹（WB）、免疫组织化学（IHC）、免疫荧光（IF）和组织芯片来评估SOX7在体外和体内的表达。此外，还使用 R 软件分析了 SOX7 表达、预后和 SOX7 + 细胞色素（CYGB）评分。用 BCa 细胞系进行了体外和体内实验，以验证 SOX7 敲除和过表达对 BCa 恶性进展的影响。结果显示，SOX7在BCa中的表达量较低。它具有多种功能，可抑制 BCa 的增殖、迁移和侵袭能力。此外，实验数据库显示，SOX7 与 DNA 甲基转移酶 3 beta（DNMT3B）的启动子结合，导致 DNMT3B 的转录抑制。这随后导致 CYGB 启动子的甲基化减少，最终抑制了 BCa 的肿瘤进展。SOX7 + CYGB评分与患者的预后密切相关。总之，SOX7 通过 DNMT3B/CYGB 轴抑制 BCa 的恶性进展。此外，SOX7 + CYGB 评分还能预测 BCa 患者的预后结果。因此，SOX7和CYGB可能在膀胱癌的进展过程中发挥重要作用，可作为膀胱癌患者的预后标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊